Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells

Basit Öğe Kaydı
dc.contributor.authorDogan, Fatma
dc.contributor.authorOzates, Neslihan Pinar
dc.contributor.authorBagca, Bakiye Goker
dc.contributor.authorAbbaszadeh, Zeka
dc.contributor.authorSogutlu, Fatma
dc.contributor.authorGasimli, Roya
dc.contributor.authorGunduz, Cumhur
dc.contributor.authorAvci, Cigir Biray
dc.date.accessioned2019-10-27T09:46:30Z
dc.date.available2019-10-27T09:46:30Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractIt is emphasized that cancer stem cells (CSCs) forming the subpopulation of tumour cells are responsible for tumour growth, metastasis, and cancer drug resistance. Inadequate response to conventional therapy in breast cancer leads researchers to find new treatment methods and literature surveys that support CSC studies. A selective anticancer agent BIBR1532 inhibits the telomerase enzyme. Many of the chemotherapeutic drugs used in clinical trials have harmful effects, but the advantage of telomerase-based inhibitors is that they are less toxic to healthy tissues. The phosphoinositide 3-kinase (PI3K)/serine/threonine kinase (Akt)/mammalian target of rapamycin (mTOR) pathway is common in breast cancer, and the interaction between the mTOR pathway and human telomerase reverse transcriptase (hTERT) is essential for the survival of cancer cells. In our study, we treated MCF-7, breast cancer stem cell (BCSC) and normal breast epithelial cell MCF10A with the BIBR1532 inhibitor. The IC (50) doses for the 48th hour of BIBR1532 treatment were detected as 34.59M in MCF-7, 29.91M in BCSCs, and 29.07M in MCF10A. It has been observed that this agent induces apoptosis in the BCSC and MCF-7 cell lines. According to the results of cell cycle analysis, G (2)/M phase accumulation was observed in BCSC and MCF-7 cell lines. It has also been shown that BIBR1532 suppresses telomerase activity in BCSC and MCF-7. The effect of BIBR1532 on the mTOR signalling pathway has been investigated for the first time in this study. It is thought that the telomerase inhibitor may bring a new approach to the treatment and it may be useful in the treatment of CSCs.en_US
dc.description.sponsorshipEge Universitesi [17-TIP-038]en_US
dc.description.sponsorshipEge Universitesi, Grant/Award Number: 17-TIP-038en_US
dc.identifier.doi10.1002/jcb.27089en_US
dc.identifier.endpage1293en_US
dc.identifier.issn0730-2312
dc.identifier.issn1097-4644
dc.identifier.issue2en_US
dc.identifier.pmid30368861en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1282en_US
dc.identifier.urihttps://doi.org/10.1002/jcb.27089
dc.identifier.urihttps://hdl.handle.net/11454/29284
dc.identifier.volume120en_US
dc.identifier.wosWOS:000458822400022en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Cellular Biochemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBIBR1532en_US
dc.subjectbreast cancer stem cellen_US
dc.subjectMCF10Aen_US
dc.subjectMCF-7en_US
dc.subjectmTOR pathwayen_US
dc.subjecttelomerase inhibitoren_US
dc.titleInvestigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cellsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu